Apricus Biosciences, Inc. (APRI)
Q2 2012 Earnings Call
August 10, 2012 10:30 AM ET
Ed Cox – VP, IR and Corporate Development
Bassam Damaj – CEO and President
Steve Martin – SVP and CFO
Jason Butler – JMP Securities
Scott Henry – ROTH Capital Partners
Greetings. Welcome to the Apricus Biosciences’ Second Quarter 2012 Results Conference. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mr. Ed Cox, Vice President of Investor Relations and Corporate Development for Apricus Biosciences. Thank you. You may begin.
Good afternoon and thank you for joining us today. I am Ed Cox, Vice President of Corporate Development and Investor Relations here at Apricus Bio. With me from Apricus, are Dr. Bassam Damaj, President and Chief Executive Officer, and Steve Martin, our Chief Financial Officer.
During the call, Bassam will review the recent corporate events and Steve will discuss the second quarter financial results. Bassam will then recap the company’s upcoming milestones and provide a brief update before opening the call for questions.
Before we begin, let me remind you, during today’s conference call the management team will make forward-looking statements regarding future events or future financial performance of the company. Please keep in mind that such statements are predictions based on current expectations and actual results could differ materially. You should refer to our most recent filings with the Securities and Exchange Commission for an additional discussion on factors affecting our business.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts